

Our ref: FOI 966

14th March 2022

FOI Response 966

Q1

How many patients were treated by your Trust in the last 3 months with the following drugs

Adalimumab (Amgevita)

Adalimumab (Humira)

Adalimumab (Hyrimoz)

Adalimumab (Idacio)

Adalimumab (Imraldi)

	RHEUM	DERM	GASTRO	OTHERS	TOTAL
Adalimumab (Amgevita)	63	61	26	0	150
Adalimumab (Humira)	45	28	6	0	79
Adalimumab (Hyrimoz)	0	0	0	0	0
Adalimumab (Idacio)	0	0	0	0	0
Adalimumab (Imraldi)	332	119	137	<5	590

Q2

Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible please provide new patients number by

New Humira patients - all departments

New Humira patients - rheumatology

New Humira patients - dermatology

New Humira patients – gastroenterology

New Humira patients - all departments	0
New Humira patients - rheumatology	0
New Humira patients - dermatology	0
New Humira patients – gastroenterology	0

Q3

Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimioz, Idacio, Imraldi etc) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible provide new patients numbers by department

New Adalimumab Biosimilar patients - all departments

New Adalimumab Biosimilar patients – rheumatology

New Adalimumab Biosimilar patients – dermatology

New Adalimumab Biosimilar patients – gastroenterology

New Adalimumab Biosimilar patients - all departments	258
New Adalimumab Biosimilar patients – rheumatology	124
New Adalimumab Biosimilar patients – dermatology	69
New Adalimumab Biosimilar patients – gastroenterology	65

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net